Literature DB >> 34914835

Higher Angiotensin II Type 1 Receptor Levels and Activity in the Postmortem Brains of Older Persons with Alzheimer's Dementia.

Caglar Cosarderelioglu1,2,3, Lolita S Nidadavolu1, Claudene J George4, Ruth Marx-Rattner1, Laura Powell1, Qian-Li Xue1,5, Jing Tian6, Joy Salib1, Esther S Oh1, Luigi Ferrucci7, Pervin Dincer3, David A Bennett8, Jeremy D Walston1, Peter M Abadir1.   

Abstract

Aging is a key risk factor in Alzheimer's dementia (AD) development and progression. The primary dementia-protective benefits of angiotensin II subtype 1 receptor (AT1R) blockers are believed to arise from systemic effects on blood pressure. However, a brain-specific renin-angiotensin system (b-RAS) exists, which can be altered by AT1R blockers. Brain RAS acts mainly through 3 angiotensin receptors: AT1R, AT2R, and AT4R. Changes in these brain angiotensin receptors may accelerate the progression of AD. Using postmortem frontal cortex brain samples of age- and sex-matched cognitively normal individuals (n = 30) and AD patients (n = 30), we sought to dissect the b-RAS changes associated with AD and assess how these changes correlate with brain markers of oxidative stress, inflammation, and mitochondrial dysfunction as well as amyloid-β and paired helical filament tau pathologies. Our results show higher protein levels of the pro-inflammatory AT1R and phospho-ERK (pERK) in the brains of AD participants. Brain AT1R levels and pERK correlated with higher oxidative stress, lower cognitive performance, and higher tangle and amyloid-β scores. This study identifies molecular changes in b-RAS and offers insight into the role of b-RAS in AD-related brain pathology.
© The Author(s) 2021. Published by Oxford University Press on behalf of The Gerontological Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Aging; Central nervous system; Inflammation; Oxidative stress; Renin-angiotensin system

Mesh:

Substances:

Year:  2022        PMID: 34914835      PMCID: PMC8974324          DOI: 10.1093/gerona/glab376

Source DB:  PubMed          Journal:  J Gerontol A Biol Sci Med Sci        ISSN: 1079-5006            Impact factor:   6.591


  65 in total

Review 1.  Angiotensin II type 2 receptor (AT2R) in renal and cardiovascular disease.

Authors:  Bryna S M Chow; Terri J Allen
Journal:  Clin Sci (Lond)       Date:  2016-08-01       Impact factor: 6.124

2.  Angiotensin IV Receptors Mediate the Cognitive and Cerebrovascular Benefits of Losartan in a Mouse Model of Alzheimer's Disease.

Authors:  Jessika Royea; Luqing Zhang; Xin-Kang Tong; Edith Hamel
Journal:  J Neurosci       Date:  2017-05-05       Impact factor: 6.167

Review 3.  mRNAs, proteins and the emerging principles of gene expression control.

Authors:  Christopher Buccitelli; Matthias Selbach
Journal:  Nat Rev Genet       Date:  2020-07-24       Impact factor: 53.242

4.  Protective effects of intranasal losartan in the APP/PS1 transgenic mouse model of Alzheimer disease.

Authors:  Lusine Danielyan; Roman Klein; Leah R Hanson; Marine Buadze; Matthias Schwab; Christoph H Gleiter; William H Frey
Journal:  Rejuvenation Res       Date:  2010 Apr-Jun       Impact factor: 4.663

5.  Angiotensin II triggers autophagy and apoptosis in PC12 cell line: An in vitro Alzheimer's disease model.

Authors:  Minjie Tian; Xingjian Lin; Liang Wu; Jie Lu; Yingdong Zhang; Jingping Shi
Journal:  Brain Res       Date:  2019-05-02       Impact factor: 3.252

6.  Discordant protein and mRNA expression in lung adenocarcinomas.

Authors:  Guoan Chen; Tarek G Gharib; Chiang-Ching Huang; Jeremy M G Taylor; David E Misek; Sharon L R Kardia; Thomas J Giordano; Mark D Iannettoni; Mark B Orringer; Samir M Hanash; David G Beer
Journal:  Mol Cell Proteomics       Date:  2002-04       Impact factor: 5.911

7.  Central angiotensin II-induced Alzheimer-like tau phosphorylation in normal rat brains.

Authors:  Minjie Tian; Donglin Zhu; Wei Xie; Jingping Shi
Journal:  FEBS Lett       Date:  2012-09-13       Impact factor: 4.124

Review 8.  The Coming of Age of the Angiotensin Hypothesis in Alzheimer's Disease: Progress Toward Disease Prevention and Treatment?

Authors:  Patrick Gavin Kehoe
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

9.  Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis.

Authors:  Nien-Chen Li; Austin Lee; Rachel A Whitmer; Miia Kivipelto; Elizabeth Lawler; Lewis E Kazis; Benjamin Wolozin
Journal:  BMJ       Date:  2010-01-12

Review 10.  Brain Renin-Angiotensin System at the Intersect of Physical and Cognitive Frailty.

Authors:  Caglar Cosarderelioglu; Lolita S Nidadavolu; Claudene J George; Esther S Oh; David A Bennett; Jeremy D Walston; Peter M Abadir
Journal:  Front Neurosci       Date:  2020-09-30       Impact factor: 4.677

View more
  4 in total

1.  Losartan Mitigates Oxidative Stress in the Brains of Aged and Inflamed IL-10-/- Mice.

Authors:  Nazaneen Saleh; Caglar Cosarderelioglu; Ramya Vajapey; Jeremy Walston; Peter M Abadir
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2022-09-01       Impact factor: 6.591

2.  Angiotensin Type-1 Receptor Inhibition Reduces NLRP3 Inflammasome Upregulation Induced by Aging and Neurodegeneration in the Substantia Nigra of Male Rodents and Primary Mesencephalic Cultures.

Authors:  Aloia Quijano; Carmen Diaz-Ruiz; Andrea Lopez-Lopez; Begoña Villar-Cheda; Ana Muñoz; Ana I Rodriguez-Perez; Jose L Labandeira-Garcia
Journal:  Antioxidants (Basel)       Date:  2022-02-08

3.  Dysregulation of ACE-1 in Normal Aging and the Early Stages of Alzheimer's Disease.

Authors:  Robert MacLachlan; Patrick Gavin Kehoe; J Scott Miners
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2022-09-01       Impact factor: 6.591

Review 4.  Roles of traditional chinese medicine regulating neuroendocrinology on AD treatment.

Authors:  Chujun Deng; Huize Chen; Zeyu Meng; Shengxi Meng
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-21       Impact factor: 6.055

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.